Long-Term Outcomes of Nivolumab and Ipilimumab Combination in Unresectable Advanced Melanoma
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on February 03rd, 2025
|
Following its approval in 2010, the combination of nivolumab and ipilimumab has shown remarkable outcomes in patients with melanoma. Nivolumab and ipilimumab function by blocking the PD-1 and CTLA-4 proteins that cancer cells use to suppress the immune response. After the approval, Bristol Myers Squibb sponsored a surveillance study to assess the long-term outcomes of the nivolumab and ipilimumab combination in treating melanoma.
The clinical study included 1,296 participants diagnosed with unresectable stage III and IV melanoma. Patients were randomly assigned to receive either nivolumab, ipilimumab, or the combination of both. Nivolumab was administered intravenously every 2 weeks at a dose of 3 mg per kilogram of body weight, while ipilimumab was given every 2 weeks at a similar dose, but only for 4 doses. Patients in the combination therapy group followed a slightly different regimen, starting with an induction phase consisting of 1 mg per kilogram of nivolumab and 3 mg per kilogram of ipilimumab every 3 weeks for 4 doses. Afterward, patients entered a maintenance phase, receiving only nivolumab at a higher dose of 3 mg per kilogram every 2 weeks.
After 10 years of follow-up, the researchers found that the melanoma-specific survival rate in the combination therapy group was 52%, significantly higher than in the monotherapy groups. Additionally, the 3-year progression-free survival rate was higher in the combination therapy group at 39%, which remained at 31% after 10 years. Subgroup analysis of patients with BRAF mutations revealed a melanoma-specific survival rate of 56% in the combination therapy group. The researchers noted that the inclusion of ipilimumab in the treatment regimen was associated with a higher incidence of adverse events, suggesting the need for alternative combination therapies targeting other immune evasion mechanisms in tumors.
The clinical study included 1,296 participants diagnosed with unresectable stage III and IV melanoma. Patients were randomly assigned to receive either nivolumab, ipilimumab, or the combination of both. Nivolumab was administered intravenously every 2 weeks at a dose of 3 mg per kilogram of body weight, while ipilimumab was given every 2 weeks at a similar dose, but only for 4 doses. Patients in the combination therapy group followed a slightly different regimen, starting with an induction phase consisting of 1 mg per kilogram of nivolumab and 3 mg per kilogram of ipilimumab every 3 weeks for 4 doses. Afterward, patients entered a maintenance phase, receiving only nivolumab at a higher dose of 3 mg per kilogram every 2 weeks.
After 10 years of follow-up, the researchers found that the melanoma-specific survival rate in the combination therapy group was 52%, significantly higher than in the monotherapy groups. Additionally, the 3-year progression-free survival rate was higher in the combination therapy group at 39%, which remained at 31% after 10 years. Subgroup analysis of patients with BRAF mutations revealed a melanoma-specific survival rate of 56% in the combination therapy group. The researchers noted that the inclusion of ipilimumab in the treatment regimen was associated with a higher incidence of adverse events, suggesting the need for alternative combination therapies targeting other immune evasion mechanisms in tumors.